Literature DB >> 17361995

Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase.

Michael N Greco1, Michael J Hawkins, Eugene T Powell, Harold R Almond, Lawrence de Garavilla, Jeffrey Hall, Lisa K Minor, Yuanping Wang, Thomas W Corcoran, Enrico Di Cera, Angelene M Cantwell, Savvas N Savvides, Bruce P Damiano, Bruce E Maryanoff.   

Abstract

A series of beta-carboxamido-phosphon(in)ic acids (2) was identified as a new structural motif for obtaining potent inhibitors of human mast cell chymase. For example, 1-naphthyl derivative 5f had an IC50 value of 29 nM and (E)-styryl derivative 6g had an IC50 value of 3.5 nM. An X-ray structure for 5f.chymase revealed key interactions within the enzyme active site. Compound 5f was selective for inhibiting chymase versus eight serine proteases. Compound 6h was orally bioavailable in rats (F=39%), and orally efficacious in a hamster model of inflammation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17361995     DOI: 10.1021/jm0700619

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  12 in total

1.  Synthesis of indole analogues of the natural schweinfurthins.

Authors:  John G Kodet; David F Wiemer
Journal:  J Org Chem       Date:  2013-09-05       Impact factor: 4.354

2.  Discovery and Design of First Benzylamine-Based Ligands Binding to an Unlocked Conformation of the Complement Factor D.

Authors:  Anna Vulpetti; Nils Ostermann; Stefan Randl; Taeyoung Yoon; Aengus Mac Sweeney; Frederic Cumin; Edwige Lorthiois; Simon Rüdisser; Paul Erbel; Jürgen Maibaum
Journal:  ACS Med Chem Lett       Date:  2018-04-24       Impact factor: 4.345

Review 3.  Mast cell peptidases: chameleons of innate immunity and host defense.

Authors:  Neil N Trivedi; George H Caughey
Journal:  Am J Respir Cell Mol Biol       Date:  2009-11-20       Impact factor: 6.914

4.  Expression of recombinant human mast cell chymase with Asn-linked glycans in glycoengineered Pichia pastoris.

Authors:  Eliot T Smith; Evan T Perry; Megan B Sears; David A Johnson
Journal:  Protein Expr Purif       Date:  2014-08-12       Impact factor: 1.650

Review 5.  Chymase inhibitors for the treatment of cardiac diseases: a patent review (2010-2018).

Authors:  Sarfaraz Ahmad; Carlos M Ferrario
Journal:  Expert Opin Ther Pat       Date:  2018-10-10       Impact factor: 6.674

6.  Guinea pig chymase is leucine-specific: a novel example of functional plasticity in the chymase/granzyme family of serine peptidases.

Authors:  George H Caughey; Jeremy Beauchamp; Daniel Schlatter; Wilfred W Raymond; Neil N Trivedi; David Banner; Harald Mauser; Jürgen Fingerle
Journal:  J Biol Chem       Date:  2008-03-19       Impact factor: 5.157

7.  A combination of receptor-based pharmacophore modeling & QM techniques for identification of human chymase inhibitors.

Authors:  Mahreen Arooj; Sugunadevi Sakkiah; Songmi Kim; Venkatesh Arulalapperumal; Keun Woo Lee
Journal:  PLoS One       Date:  2013-04-26       Impact factor: 3.240

8.  3D QSAR pharmacophore modeling, in silico screening, and density functional theory (DFT) approaches for identification of human chymase inhibitors.

Authors:  Mahreen Arooj; Sundarapandian Thangapandian; Shalini John; Swan Hwang; Jong Keun Park; Keun Woo Lee
Journal:  Int J Mol Sci       Date:  2011-12-12       Impact factor: 5.923

9.  Crystal structure of a complex of human chymase with its benzimidazole derived inhibitor.

Authors:  Yoshiyuki Matsumoto; Shinji Kakuda; Masahiro Koizumi; Tsuyoshi Mizuno; Yumiko Muroga; Takashi Kawamura; Midori Takimoto-Kamimura
Journal:  J Synchrotron Radiat       Date:  2013-09-25       Impact factor: 2.616

10.  Molecular modeling study for inhibition mechanism of human chymase and its application in inhibitor design.

Authors:  Mahreen Arooj; Songmi Kim; Sugunadevi Sakkiah; Guang Ping Cao; Yuno Lee; Keun Woo Lee
Journal:  PLoS One       Date:  2013-04-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.